Guangjun Jing

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial

Zhiling Yan, Jiang Cao, Hai Cheng et al. · The Lancet Haematology · 2019 · 317 citations

Life Sciences, Hematology, Immunology +16

Potent anti‐leukemia activities of humanized CD19‐targeted Chimeric antigen receptor T (CAR‐T) cells in patients with relapsed/refractory acute lymphoblastic leukemia

Jiang Cao, Gang Wang, Hai Cheng et al. · American Journal of Hematology · 2018 · 174 citations · Full text

Life Sciences, Immunology, Oncology +17

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

Ying Wang, Chunrui Li, Jieyun Xia et al. · Blood Advances · 2021 · 102 citations · Full text

Life Sciences, Hematology, Immunology +17

Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies

Ying Wang, Kunming Qi, Hai Cheng et al. · Biology of Blood and Marrow Transplantation · 2019 · 96 citations · Full text

Medicine, Hematology, Oncology +17

ATF4 is a novel regulator of MCP-1 in microvascular endothelial cells

Hui‐Bin Huang, Guangjun Jing, Joshua J. Wang et al. · Journal of Inflammation · 2015 · 56 citations · Full text

Life Sciences, Immunology, Molecular Biology +17